Table 3. Mutation profile according to cytogenetic abnormality and de novo and secondary/relapsed cases.

Gene	CN-AML (n=77)	CA-AML(n=26)	P	De novo (n=93)	Secondary or relapsed (n=12)	P
ASXL1	6(7.8%)	3(11.5 %)	.689	8(8.6%)	1(8.3%)	1.000
BRAF	0(0.0%)	0(0.0 %)	-	0(0.0%)	0(0.0%)	-
CBL	0(0.0%)	0(0.0 %)		0(0.0%)	0(0.0%)	-
CEBPA	9(11.7%)	1(3.8 %)	.445	10(10.8%)	0(0.0%)	.600
DNMT3A	17(22.1%)	0(0.0 %)	.006	17(18.3%)	0(0.0%)	.208
FLT3-ITD	28(36.4%)	3(11.5 %)	.017	31(33.3%)	1(8.3%)	.101
FLT3-TKD	4(5.2%)	1(3.8 %)	1.000	5(5.4%)	0(0.0%)	1.000
IDH1	7(9.1%)	1(3.8 %)	.676	7(7.5%)	1(8.3%)	1.000
IDH2	8(10.4%)	2(7.7 %)	1.000	9(9.7%)	1(8.3%)	1.000
JAK2	3(3.9%)	0(0.0 %)	.570	1(1.1%)	2(16.7%)	.034
KIT	0(0.0%)	2(7.7 %)	.062	1(1.1%)	1(8.3%)	.216
KRAS	0(0.0%)	0(0.0 %)	-	0(0.0%)	0(0.0%)	-
NPM1	23(29.9%)	0(0.0 %)	.002	23(24.7%)	0(0.0%)	.064
NRAS	6(7.8%)	3(11.5 %)	.689	6(6.5%)	3(25.0%)	.065
PTPN11	3(3.9%)	1(3.8 %)	1.000	2(2.2%)	2(16.7%)	.063
RUNX1	6(7.8%)	6(23.1 %)	.070	9(9.7%)	3(25.0%)	.138
SETD2	2(2.6%)	1(3.8 %)	1.000	3(3.2%)	0(0.0%)	1.000
TET2	11(14.3%)	0(0.0 %)	.061	11(11.8%)	1(8.3%)	1.000
TP53	0(0.0%)	3(11.5 %)	.015	2(2.2%)	1(8.3%)	.308
WT1	9(11.7%)	4(15.4 %)	.734	11(11.8%)	2(16.7%)	.642